Literature DB >> 33041652

Engagement in the Hepatitis C care continuum among people who use drugs.

Babak Tofighi1,2,3, Joshua D Lee1,2,3, Selena S Sindhu1, Chemi Chemi1, Noelle R Leonard3,4.   

Abstract

Despite high rates of Hepatitis C virus (HCV) infection among people who use drugs (PWUDs), access to the HCV care continuum combined with the receipt of medications for addiction treatment in primary care settings remains suboptimal. A qualitative study was conducted among adults admitted for inpatient detoxification for opioid use disorder (OUD) in New York City (n=23) to assess barriers and facilitators with HCV prevention, screening, treatment, interactions with primary care providers, and experiences with integrated care approaches. Study findings yielded six major themes related to HCV care. Major gaps persist in knowledge regarding HCV harm reduction strategies, voluntary HCV testing services, and eligibility for HCV treatment. Treatment coordination challenges reinforce the importance of enhancing linkages to HCV care in key access-points utilized by PWUDs (e.g., emergency rooms, specialty addiction treatment settings). Peer networks combined with frequent patient-physician communication were elicited as important factors in facilitating linkage to HCV care. Additional care coordination needs in primary care settings included access to integrated treatment of HCV and OUD, and administrative support for enrollment in Medicaid, subsidized housing, and access to transportation vouchers.

Entities:  

Keywords:  Hepatitis C; drug users; opioid use disorder; primary health care

Year:  2020        PMID: 33041652      PMCID: PMC7540221          DOI: 10.1080/14659891.2019.1704076

Source DB:  PubMed          Journal:  J Subst Use        ISSN: 1465-9891


  24 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

Authors:  Katy M E Turner; Sharon Hutchinson; Peter Vickerman; Vivian Hope; Noel Craine; Norah Palmateer; Margaret May; Avril Taylor; Daniela De Angelis; Sheila Cameron; John Parry; Margaret Lyons; David Goldberg; Elizabeth Allen; Matthew Hickman
Journal:  Addiction       Date:  2011-08-24       Impact factor: 6.526

Review 3.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

4.  High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.

Authors:  Brianna L Norton; Julia Fleming; Marcus A Bachhuber; Meredith Steinman; Joseph DeLuca; Chinazo O Cunningham; Nirah Johnson; Fabienne Laraque; Alain H Litwin
Journal:  Int J Drug Policy       Date:  2017-08-12

5.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

Authors:  Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

6.  Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.

Authors:  Davina Swan; Jean Long; Olivia Carr; Jean Flanagan; Helena Irish; Shay Keating; Michelle Keaveney; John Lambert; P Aiden McCormick; Susan McKiernan; John Moloney; Nicola Perry; Walter Cullen
Journal:  AIDS Patient Care STDS       Date:  2010-12       Impact factor: 5.078

7.  Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

Authors:  Jason Grebely; Krista A Genoway; Jesse D Raffa; Gurbir Dhadwal; Tasleem Rajan; Grey Showler; Kate Kalousek; Fiona Duncan; Mark W Tyndall; Chris Fraser; Brian Conway; Benedikt Fischer
Journal:  Drug Alcohol Depend       Date:  2007-11-09       Impact factor: 4.492

Review 8.  The social production of hepatitis C risk among injecting drug users: a qualitative synthesis.

Authors:  Tim Rhodes; Carla Treloar
Journal:  Addiction       Date:  2008-10       Impact factor: 6.526

9.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.

Authors:  Michelle A Lally; Sydney A Montstream-Quas; Sara Tanaka; Sara K Tedeschi; Kathleen M Morrow
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

10.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.